CA2666587C - Nanoparticules micellaires de substances chimiques - Google Patents

Nanoparticules micellaires de substances chimiques Download PDF

Info

Publication number
CA2666587C
CA2666587C CA2666587A CA2666587A CA2666587C CA 2666587 C CA2666587 C CA 2666587C CA 2666587 A CA2666587 A CA 2666587A CA 2666587 A CA2666587 A CA 2666587A CA 2666587 C CA2666587 C CA 2666587C
Authority
CA
Canada
Prior art keywords
micelles
mixture
poorly soluble
active substance
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2666587A
Other languages
English (en)
Other versions
CA2666587A1 (fr
Inventor
Jan P. Moeschwitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie BV
Original Assignee
AbbVie BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie BV filed Critical AbbVie BV
Publication of CA2666587A1 publication Critical patent/CA2666587A1/fr
Application granted granted Critical
Publication of CA2666587C publication Critical patent/CA2666587C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2666587A 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques Expired - Fee Related CA2666587C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85302306P 2006-10-20 2006-10-20
US60/853,023 2006-10-20
EP06122648.6 2006-10-20
EP06122648 2006-10-20
PCT/EP2007/061194 WO2008046905A1 (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques

Publications (2)

Publication Number Publication Date
CA2666587A1 CA2666587A1 (fr) 2008-04-24
CA2666587C true CA2666587C (fr) 2015-12-22

Family

ID=38661928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2666587A Expired - Fee Related CA2666587C (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques

Country Status (9)

Country Link
EP (1) EP2083799A1 (fr)
JP (1) JP5439182B2 (fr)
KR (1) KR101434334B1 (fr)
AU (1) AU2007312233B2 (fr)
CA (1) CA2666587C (fr)
EA (1) EA026213B1 (fr)
IL (1) IL197701A (fr)
NO (1) NO20091975L (fr)
WO (1) WO2008046905A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
KR20110056516A (ko) 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 점막 또는 피부를 통한 치료제의 흡수 개선
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
US20150111246A1 (en) * 2012-04-24 2015-04-23 Astrazeneca Pharmaceuticals Lp Site-specific enzymatic modification of exendins and analogs thereof
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
FR3014317B1 (fr) * 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
EP3424493A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
CA3120008A1 (fr) * 2018-11-30 2020-06-04 Canopy Growth Corporation Compositions comprenant un cannabinoide ou un compose derive du cannabis, methodes de fabrication et d'utilisation
EP4005561A4 (fr) * 2019-07-25 2022-12-07 Beijing Shenogen Pharma Group Ltd. Préparation nanomicellaire d'icaritine et son procédé de préparation et son application
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
AU2020403651A1 (en) 2019-12-09 2022-07-07 Nicoventures Trading Limited Oral product comprising a cannabinoid
CA3224601A1 (fr) * 2021-07-22 2023-01-26 Steven Alderman Composant, derive ou extrait de cannabis dans une matrice soluble dans l'eau
AU2022315590A1 (en) * 2021-07-22 2024-01-18 Nicoventures Trading Limited Composition comprising a constituent, derivative or extract of cannabis
WO2023002197A1 (fr) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Compositions comprenant un constituant, un dérivé ou un extrait de cannabis
WO2023002201A1 (fr) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Compositions comprenant des constituants, des dérivés ou des extraits de cannabis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
SI1429761T1 (sl) * 2001-09-21 2007-02-28 Solvay Pharm Bv Novi 4,5-dihidro-1h-pirazolni derivati s cb1-antagonisticno aktivnostjo
HUP0402113A3 (en) * 2001-09-21 2012-05-29 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
WO2005053727A2 (fr) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Compositions pharmaceutiques pour agents peptidiques bioactifs
AU2004308973A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP2008517976A (ja) * 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
UA100966C2 (ru) * 2005-04-08 2013-02-25 Эбботт Леборетриз Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
KR20080042039A (ko) * 2005-04-18 2008-05-14 루비콘 리서치 피브이티. 엘티디. 생물학적으로 강화된 조성물

Also Published As

Publication number Publication date
EP2083799A1 (fr) 2009-08-05
CA2666587A1 (fr) 2008-04-24
EA200900572A1 (ru) 2009-10-30
EA026213B1 (ru) 2017-03-31
KR20090077074A (ko) 2009-07-14
KR101434334B1 (ko) 2014-08-28
IL197701A (en) 2014-12-31
NO20091975L (no) 2009-07-09
AU2007312233B2 (en) 2012-09-20
WO2008046905A1 (fr) 2008-04-24
JP5439182B2 (ja) 2014-03-12
JP2010506886A (ja) 2010-03-04
IL197701A0 (en) 2009-12-24
AU2007312233A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
CA2666587C (fr) Nanoparticules micellaires de substances chimiques
US7923026B2 (en) Embedded micellar nanoparticles
US11839689B2 (en) Formulations of enzalutamide
JP7006995B2 (ja) 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法
US20090263479A1 (en) Formulations for poorly permeable active pharmaceutical ingredients
TWI392507B (zh) 包埋的膠束奈米顆粒
KR101561406B1 (ko) 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
ES2663721T3 (es) Formulaciones de olmesartán
US20040001888A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
BR102016015553A2 (pt) Sistemas multiparticulados liquissólidos para administração oral, processo de obtenção dos mesmos e seus usos
CN106822122B (zh) 一种替米沙坦和氨氯地平的口服药用组合物及其制备方法
Lalani et al. LIQUISOLID COMPACT APPROACH TO ENHANCE DISSOLUTION RATE OF POORLY SOLUBLE DRUGS: A RECENT RESEARCH REVIEW.
CN113081970A (zh) 一种环孢素固体分散体及其片剂制备方法
WO2010082855A1 (fr) Compositions pharmaceutiques comprenant de la ziprasidone sous forme de base libre ou de chlorhydrate et leur méthode d'élaboration
Effiong et al. Principles, Applications and Limitations of the Liquisolid System of Drug Delivery: A Review

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201019